Scientists investigate mucus barrier to inhaled antibodies in lung disease
NCT ID NCT06670937
First seen Nov 19, 2025 · Last updated May 01, 2026 · Updated 24 times
Summary
This study looks at how mucus in the airways of people with bronchiectasis (a chronic lung condition) affects a new inhaled antibody treatment. Researchers will collect sputum samples from 30 adults to test how well the antibodies can reach and bind to bacteria. The goal is to understand barriers to treatment and help design better inhaled therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIECTASIS ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHRU de Tours
RECRUITINGTours, France, 37044, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.